Pharma Technology Investment Trends - Executive Director of Biomarker Sciences, Top 20 Pharma

An executive director at a top pharma company speaks to how they see investments in the precision medicine space occurring today and changing in the next 3 – 5 years. An expert in biomarker sciences in the oncology and infectious disease spaces, they manage budgets for clinical trials, research projects, and capital equipment. Currently, they see the most investment occurring in companion diagnostics, real world data, and research tools, namely genomics. While companion diagnostics and research tools directly support drug development and access to therapies, real world data investments serve this expert in understanding patient populations for clinical trials. They note that their company will continue to invest in technologies that reduce drug development timelines, allow for improved efficiencies / cut costs, and that help promote a global reach. Key trends to navigate in pursuit of these goals include the complex governance structure of a large company (e.g., having more logistics of multiple people making decisions),increased diagnostic regulations, and the FDA modernization act. The trend towards early cancer detection and associated diagnostic technologies will additionally impact investments.

‍